Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Apr 26;25(Suppl C):C79-C83.
doi: 10.1093/eurheartjsupp/suad011. eCollection 2023 May.

Drug-coated balloon combined with drug-eluting stent for the treatment of coronary bifurcation lesions: insights from the HYPER study

Dario Pellegrini  1 , Michael Donahue  2 , Damiano Regazzoli  3 , Delio Tedeschi  4 , Marco Loffi  5 , Mariano Pellicano  1 , Giuseppe De Blasio  1 , Maurizio Tespili  1 , Giulio Guagliumi  1 , Alfonso Ielasi  1
Affiliations

Drug-coated balloon combined with drug-eluting stent for the treatment of coronary bifurcation lesions: insights from the HYPER study

Dario Pellegrini et al. Eur Heart J Suppl. .

Abstract

True coronary bifurcation lesions (CBL) represent a challenging scenario for percutaneous coronary interventions (PCI), and are associated with a higher risk of target lesion failure (TLF), particularly when two stents are implanted. A hybrid strategy combining a drug-eluting stent (DES) in the main branch, and a drug-coated balloon in the side branch may improve outcomes by reducing the total stent length while maintaining an effective anti-prolipherative action. In this sub-study of the HYPER trial, 50 patients with true CBL were treated with a hybrid strategy: procedural success was 96%, one case of peri-procedural myocardial infarction and one case of TLF (in a DES-treated segment) at 1 year were reported. This study suggests that such a hybrid strategy may be a safe and effective option for true CBL PCI, and warrants additional investigations to compare outcomes with standard of care strategies.

Keywords: Bifurcation lesion; Coronary artery disease; Coronary revascularization; Coronary stenosis; Drug-coated balloon; Drug-eluting stent; Hybrid approach; Percutaneous coronary intervention; Small vessel disease.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: None declared.

References

    1. Sawaya FJ, Lefèvre T, Chevalier B, Garot P, Hovasse T, Morice MCet al. . Contemporary approach to coronary bifurcation lesion treatment. JACC Cardiovasc Interv 2016;9:1861–1878. - PubMed
    1. Lefèvre T, Louvard Y, Morice MC, Dumas P, Loubeyre C, Benslimane Aet al. . Stenting of bifurcation lesions: classification, treatments, and results. Catheter Cardiovasc Interv 2000;49:274–283. - PubMed
    1. Giustino G, Chieffo A, Palmerini T, Valgimigli M, Feres F, Abizaid Aet al. . Efficacy and safety of dual antiplatelet therapy after Complex PCI. J Am Coll Cardiol 2016;68:1851–1864. - PubMed
    1. Sharp ASP, Latib A, Ielasi A, Larosa C, Godino C, Saolini Met al. . Long-term follow-up on a large cohort of “full-metal jacket” percutaneous coronary intervention procedures. Circ Cardiovasc Interv 2009;2:416–422. - PubMed
    1. Banning AP, Lassen JF, Burzotta F, Lefèvre T, Darremont O, Hildick-Smith Det al. . Percutaneous coronary intervention for obstructive bifurcation lesions: the 14th consensus document from the European bifurcation club. EuroIntervention 2019;15:90–98. - PubMed